JP2012516691A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012516691A5 JP2012516691A5 JP2011548607A JP2011548607A JP2012516691A5 JP 2012516691 A5 JP2012516691 A5 JP 2012516691A5 JP 2011548607 A JP2011548607 A JP 2011548607A JP 2011548607 A JP2011548607 A JP 2011548607A JP 2012516691 A5 JP2012516691 A5 JP 2012516691A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- cell
- nucleic acid
- cdk6
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09001521A EP2218784A1 (en) | 2009-02-04 | 2009-02-04 | Vector(s) containing an inducible gene encoding a CDK4/CD6 inhibitor useful for treating neurodegenerative disorders |
| EP09001521.5 | 2009-02-04 | ||
| PCT/EP2010/000702 WO2010089122A2 (en) | 2009-02-04 | 2010-02-04 | Vector(s) containing an inducible gene encoding a cdk4/cdk6 inhibitor useful for treating neurodegenerative disorders or diseases associated with an unscheduled activation of the cell cycle |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012516691A JP2012516691A (ja) | 2012-07-26 |
| JP2012516691A5 true JP2012516691A5 (enExample) | 2013-03-21 |
| JP5869884B2 JP5869884B2 (ja) | 2016-02-24 |
Family
ID=40673417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011548607A Expired - Fee Related JP5869884B2 (ja) | 2009-02-04 | 2010-02-04 | 細胞周期の不定期の活性化に関連する神経変性障害または疾患の治療に有用なｃｄｋ４／ｃｄｋ６阻害剤をコードする誘導性遺伝子を含有するベクター |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20120004277A1 (enExample) |
| EP (2) | EP2218784A1 (enExample) |
| JP (1) | JP5869884B2 (enExample) |
| KR (1) | KR101378353B1 (enExample) |
| CN (1) | CN102356156A (enExample) |
| AU (1) | AU2010211289B2 (enExample) |
| CA (1) | CA2751531A1 (enExample) |
| WO (1) | WO2010089122A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8653324B2 (en) * | 2010-06-11 | 2014-02-18 | Fox Chase Cancer Center | TetO-p16 transgenic mice |
| WO2012050975A2 (en) * | 2010-09-29 | 2012-04-19 | The University Of North Carolina At Chapel Hill | Novel circular mammalian rna molecules and uses thereof |
| KR101255338B1 (ko) * | 2010-12-15 | 2013-04-16 | 포항공과대학교 산학협력단 | 표적 세포에 대한 폴리뉴클레오티드 전달체 |
| CN107320734A (zh) | 2011-04-29 | 2017-11-07 | 西莱克塔生物科技公司 | 从合成纳米载体中控制释放免疫抑制剂 |
| CN105307641A (zh) | 2013-05-03 | 2016-02-03 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
| EA201790551A1 (ru) | 2014-09-07 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору |
| US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
| EP4599848A3 (en) | 2017-03-11 | 2025-12-03 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| CN108319816B (zh) * | 2018-02-27 | 2021-04-23 | 广州大学 | 一种基于基因通路识别小分子核糖核酸的方法 |
| US12553041B2 (en) | 2019-06-04 | 2026-02-17 | Cartesian Therapeutics Inc. | Formulations and doses of pegylated uricase |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19936034C1 (de) * | 1999-07-30 | 2001-01-25 | Univ Leipzig | Rekombiniertes, neuronalspezifisch aktiviertes, transkribierbares lineares DNA-Konstrukt |
| WO2005033277A2 (en) * | 2003-09-29 | 2005-04-14 | University Of Rochester | Methods of modulating cell cycle and cell signaling pathways using biliverdin reductase |
| ATE478965T1 (de) * | 2004-07-21 | 2010-09-15 | Dana Farber Cancer Inst Inc | Lentivirusvektoren und deren verwendung |
| EP1838841A2 (en) * | 2004-12-23 | 2007-10-03 | The Ludwig Institute for Cancer Research | Engineered dopamine neurons and uses thereof |
| US20080300202A1 (en) * | 2006-05-18 | 2008-12-04 | The State of Oregon acting by and through the State Board of Higher Education on behalf of the | Subtractive transgenics |
| US9394538B2 (en) * | 2008-05-07 | 2016-07-19 | Shi-Lung Lin | Development of universal cancer drugs and vaccines |
-
2009
- 2009-02-04 EP EP09001521A patent/EP2218784A1/en not_active Withdrawn
- 2009-02-04 EP EP13159236.2A patent/EP2620447B1/en not_active Not-in-force
-
2010
- 2010-02-04 KR KR1020117020766A patent/KR101378353B1/ko not_active Expired - Fee Related
- 2010-02-04 WO PCT/EP2010/000702 patent/WO2010089122A2/en not_active Ceased
- 2010-02-04 CN CN2010800127623A patent/CN102356156A/zh active Pending
- 2010-02-04 CA CA2751531A patent/CA2751531A1/en not_active Abandoned
- 2010-02-04 JP JP2011548607A patent/JP5869884B2/ja not_active Expired - Fee Related
- 2010-02-04 AU AU2010211289A patent/AU2010211289B2/en not_active Ceased
- 2010-02-04 US US13/146,592 patent/US20120004277A1/en not_active Abandoned
-
2016
- 2016-01-29 US US15/011,092 patent/US20160144054A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nitta et al. | Minimal Purkinje cell-specific PCP2/L7 promoter virally available for rodents and non-human primates | |
| Niepmann | Hepatitis C virus RNA translation | |
| Ren et al. | Human metapneumovirus M2-2 protein inhibits innate cellular signaling by targeting MAVS | |
| JP7651190B2 (ja) | 遺伝子操作ｒｎａを用いた内因性ａｄａｒによる標的化ｒｎａ編集 | |
| Kawagishi et al. | Reverse genetics for fusogenic bat-borne orthoreovirus associated with acute respiratory tract infections in humans: Role of outer capsid protein σC in viral replication and pathogenesis | |
| AU2019357450A1 (en) | Methods and compositions for editing rnas | |
| JP2019089787A5 (enExample) | ||
| JP2008056679A5 (enExample) | ||
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| Takahashi et al. | Reversible gene regulation in mammalian cells using riboswitch-engineered vesicular stomatitis virus vector | |
| US20210403949A1 (en) | Vector system for expressing regulatory rna | |
| CN112930395A (zh) | 靶向rna的融合蛋白组合物和使用方法 | |
| Dhungel et al. | MicroRNA-regulated gene delivery systems for research and therapeutic purposes | |
| JP2012136542A5 (enExample) | ||
| JP2008545406A5 (enExample) | ||
| WO2015126927A2 (en) | Compositions for the inactivation of virus replication and methods of making and using the same | |
| HK1202434A1 (en) | Virus vectors for highly efficient transgene delivery | |
| JP2017538401A5 (enExample) | ||
| FI3546585T3 (fi) | Muokatun intronin käsittäviä nukleiinihappoja käytettäviksi hyperbilirubinemian hoidossa | |
| WO2010127166A4 (en) | Combination anti-hiv vectors, targeting vectors, and methods of use | |
| Punnarak et al. | RNA aptamers inhibit the growth of the fish pathogen viral hemorrhagic septicemia virus (VHSV) | |
| Mariyanna et al. | Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase | |
| JP2019503205A (ja) | 自己切断リボザイムのアプタマー媒介性制御を通じての遺伝子発現制御 | |
| Oishi et al. | Identification of novel amino acid residues of influenza virus PA-X that are important for PA-X shutoff activity by using yeast | |
| Alijani et al. | Evaluation of the effect of miR-26b up-regulation on HbF expression in erythroleukemic K-562 cell line |